Brief by Shorts91 Newsdesk / 05:54am on 15 Mar 2024,Friday Health & Wellness
The FDA greenlights Rezdiffra (resmetirom) as the first drug to tackle nonalcoholic steatohepatitis (NASH), a severe liver condition affecting millions in the U.S. NASH results from liver inflammation due to excess fat, often leading to scarring and dysfunction. Rezdiffra targets liver damage directly, offering hope alongside diet and exercise for NASH patients with notable scarring. Roughly 6-8 million Americans suffer from moderate to advanced NASH. The drug's mechanism involves reducing liver fat accumulation, albeit with common side effects like diarrhea and nausea. However, caution is advised for patients with cirrhosis, emphasizing vigilance for worsening liver function.
